肺炎链球菌对β-内酰胺类抗生素耐药机制的研究进展  

Research progress of resistance mechanism of Streptococcus pneumoniae againstβ-lactams antibiotics

作　　者：谭赛娟 彭华保[1] 陈虹亮[1] TAN Saijuan;PENG Huabao;CHEN Hongliang(Department of Neonatology, the First People’s Hospital of Chenzhou Affiliated to University of South China,Chenzhou 423000, Hunan,China)

机构地区：[1]南华大学附属郴州市第一人民医院新生儿科,湖南郴州423000

出　　处：《中南医学科学杂志》2020年第4期342-345,363,共5页Medical Science Journal of Central South China

基　　金：郴州市科技局科技发展计划项目(zdyf201841);郴州市第一人民医院教学改革课题(JG2018-011).

摘　　要：肺炎链球菌(Streptococcus pneumoniae)是儿童社区获得性感染最常见细菌病原体,严重危害人类健康。β-内酰胺类抗生素是治疗肺炎链球菌感染最常用的药物。自1928年英国细菌学家亚历山大·弗莱明发现世界上第一种抗生素—青霉素以来,人类越来越依赖于抗生素,从而导致抗生素长期过度使用,使得肺炎链球菌对β-内酰胺类抗生素的耐药性迅速增加,每年造成200万人死亡。本文拟从产β-内酰胺酶、青霉素结合蛋白基因的改变等方面综述肺炎链球菌对β-内酰胺类抗生素的耐药机制。Streptococcus pneumoniae is the most common bacterial pathogen of community acquired in children,being seriously harmful to human health.β-lactam antibiotics are the most frequently drugs used in the treatment of Streptococcus pneumoniae infection.Since the first antibiotic penicillin was discovered by Alexander Fleming-a British bacteriologist-in the world in 1928,people have become more and more dependent on antibiotics,resulting in the long-term overuse of antibiotics,the resistance of Streptococcus pneumoniae toβ-lactam antibiotics increasing rapidly and more than 2 million deaths every year.In this paper,the mechanism of resistance of Streptococcus pneumoniae toβ-lactamases was reviewed includingβ-lactamase production,the change of penicillin binding protein gene and so on.

关 键 词：肺炎链球菌 Β-内酰胺类药物 耐药机制 

分 类 号：R563.1[医药卫生—呼吸系统]